Brazil
Hepatitis B
Download HBV dataHBV National Action Plan
HBV elimination goal
National prevalence survey within the last 5 years
Partially Adopted
Estimates of economic burden
Partially Adopted
Routine official reports to monitor mortality
Adopted
System for monitoring testing and treatment
Adopted
HepB birth dose policy
Yes
Year of birth dose introduction
1998
Eligible for HBV generic medicines
Licensed point-of-care PCR testing to detect HBV
Adopted
No patient co-pays for HBsAg testing
Adopted
Recommendations for HBV testing of pregnant women
Adopted
HBV testing recommendations for key population (i.e. migrants, foreign-born, etc)
Adopted
National treatment guidelines exist
Adopted
Simplified care: No treatment co-pays
Adopted
Public budget line for testing and treatment
Adopted
HCV National Action Plan
HCV elimination goal
Year of HCV elimination goal
2030
Routine official reports to monitor mortality
Adopted
System for monitoring testing and treatment
Adopted
Recommendations for HCV testing of pregnant women
Adopted
Registration of originator HCV DAAs
Adopted
Eligible for HCV generic medicines
Registration of generic HCV DAAs
Adopted
Licensed point-of-care PCR testing to detect HCV
Adopted
HCV testing policy
Risk-based
HCV testing recommendations for key population (i.e. PWID)
Adopted
No patient co-pays for anti-HCV testing
Adopted
National treatment guidelines exist
Adopted
Simplified care: Non-specialists can prescribe treatment
Adopted
Simplified care: No treatment co-pays
Adopted
No fibrosis restrictions
Adopted
No sobriety restrictions
Partially Adopted
National policy for harm reduction for persons who inject drugs
Adopted
National policy for syringe exchange in federal prisons
Not Adopted
At least one needle-syringe exchange program (NSP) operational
No
At least one opioid substitution therapy (OST) program operational
No
OST in at least one prison
Decriminalization of possession of syringes and paraphernalia
Not Adopted
Public budget line for testing and treatment
Adopted
Hepatitis C
Download HCV dataHBV National Action Plan
HBV elimination goal
National prevalence survey within the last 5 years
Partially Adopted
Estimates of economic burden
Partially Adopted
Routine official reports to monitor mortality
Adopted
System for monitoring testing and treatment
Adopted
HepB birth dose policy
Yes
Year of birth dose introduction
1998
Eligible for HBV generic medicines
Licensed point-of-care PCR testing to detect HBV
Adopted
No patient co-pays for HBsAg testing
Adopted
Recommendations for HBV testing of pregnant women
Adopted
HBV testing recommendations for key population (i.e. migrants, foreign-born, etc)
Adopted
National treatment guidelines exist
Adopted
Simplified care: No treatment co-pays
Adopted
Public budget line for testing and treatment
Adopted
HCV National Action Plan
HCV elimination goal
Year of HCV elimination goal
2030
Routine official reports to monitor mortality
Adopted
System for monitoring testing and treatment
Adopted
Recommendations for HCV testing of pregnant women
Adopted
Registration of originator HCV DAAs
Adopted
Eligible for HCV generic medicines
Registration of generic HCV DAAs
Adopted
Licensed point-of-care PCR testing to detect HCV
Adopted
HCV testing policy
Risk-based
HCV testing recommendations for key population (i.e. PWID)
Adopted
No patient co-pays for anti-HCV testing
Adopted
National treatment guidelines exist
Adopted
Simplified care: Non-specialists can prescribe treatment
Adopted
Simplified care: No treatment co-pays
Adopted
No fibrosis restrictions
Adopted
No sobriety restrictions
Partially Adopted
National policy for harm reduction for persons who inject drugs
Adopted
National policy for syringe exchange in federal prisons
Not Adopted
At least one needle-syringe exchange program (NSP) operational
No
At least one opioid substitution therapy (OST) program operational
No
OST in at least one prison
Decriminalization of possession of syringes and paraphernalia
Not Adopted
Public budget line for testing and treatment
Adopted
Overview
HBV elimination goal
HCV elimination goal
Prevalence (national)
Modelled
Survey/surveillance
Hepatitis related deaths (national)
Modelled
HBV
5,450
2019
(4,858 - 6,140)
IHME, GBD 2019 (accessed 2020)
Survey/surveillance
HBV
368
2020
Ministério da Saúde, Brasil: Boletim Epidemiologico de Hepatites Virais - 2021
HBV chart
Modelled
HCV
9,936
2019
(8,915 - 11,066)
IHME, GBD 2019 (accessed 2022)
Survey/surveillance
HCV
1,405
2020
Ministério da Saúde, Brasil: Boletim Epidemiologico de Hepatites Virais - 2021
HCV chart
Prevalence < 5
HBV
0.03
(%)
2020, latest modelled
(0.02 - 0.03(%))
WHO
No. of syringes/PWID/year
Survey/surveillance
No data available
Eligible for HBV generic medicines
Eligible for HCV generic medicines
